Crossmark

SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis

Published Online: 2021-05-13

Published Print: 2021-12

Authors

Potier, Louis https://orcid.org/0000-0001-6268-7360
Mohammedi, Kamel

Velho, Gilberto

Roussel, Ronan
License Information

Text and Data Mining valid from 2021-05-13

Version of Record valid from 2021-05-13
More Information

Article History

Received: 5 May 2021

Accepted: 8 May 2021

First Online: 13 May 2021

Declarations

:

: Not applicable.

: Not applicable.

: LP reports grants, personal fees and non-financial support from NOVO NORDISK, grants, personal fees and non-financial support from SANOFI, personal fees and non-financial support from ELI LILLY, non-financial support from SERVIER, outside the submitted work and all modest. RR reports grants, personal fees and non-financial support from sanofi, personal fees and non-financial support from MSD, grants from Amgen, personal fees from Physiogenex, personal fees from Astra-Zeneca, grants and personal fees from Novo Nordisk, personal fees from Janssen, personal fees from Eli Lilly, personal fees from Abbott, personal fees from Medtronic, personal fees from Servier, outside the submitted work and all modest. KM reports personal fees and non-financial support from Novo Nordisk and Sanofi and non-financial support from VitalAir. GV have nothing to disclose.

Document is current